Sana Aslam

By Imran Ahmad Khan, Noor ul Amin Mohsin, Sana Aslam and Matloob Ahmad

Cancer is the most lethal ailment throughout the world in the present era. The development of new anticancer remedies with minor unhealthful effects and an alternate mechanism is crucial. Benzimidazole is a distinguished heterocyclic compound and is now recognized as the privileged scaffold for new drug discovery. This chapter deals with the anticancer capability of benzimidazolium salts and their metal complexes. The benzimidazolium derivatives have been prepared by the introduction of aliphatic and aromatic groups at two nitrogen atoms of the benzimidazole ring. Other modifications include hybridization with other pharmacophores and the preparation of metal complexes. The potent derivatives presented in this review can serve as novel drug candidates against cancer.

Part of the book: Benzimidazole

By Ayesha Rafiq, Sana Aslam, Matloob Ahmad, Muhammad Jawwad Saif, Sami A. Al-Hussain and Magdi E.A. Zaki

Heterocyclic ring systems are gaining attention due to their pivotal role in drug design and medicinal chemistry. Quinazolines are nitrogen-containing heterocyclic pharmacophoric units found in abundance in natural and pharmaceutical products. Imidazoquinazolines and benzimidazoquinazolines are fused tricyclic and tetracyclic heterocyclic moieties, respectively. Different isomeric forms of imidazoquinazolines and benzimidazoquinazolines exhibited a plethora of biological applications such as antitumor, antimicrobial, antioxidant, anti-inflammatory, antitubercular, anticancer, antihypertensive, anticonvulsant, antiviral, antimalarial, antiapoptotic, anti-proliferative activities, etc. This chapter addressed the recent synthetic strategies for medicinally privileged scaffolds; imidazoquinazolines and benzimidazoquinazolines. The synthetic routes of various isomeric forms of above-mentioned heterocycles have also been discussed.

Part of the book: Recent Advances on Quinazoline

By Tooba Jabeen, Sana Aslam, Matloob Ahmad, Atta ul Haq, Sami A. Al-Hussain and Magdi E.A. Zaki

Triazoloquinazoline is a fused heterocyclic nucleus, formed by the fusion of two fundamental heterocyclic moieties; triazole and quinazoline. This class of compound is known for its potential as a therapeutic agent and is endowed with several pharmacological applications. Triazoloquinazoline and its derivatives have shown a variety of biological applications such as anticancer, anti-inflammatory, antimicrobial, antiviral, antihypertensive, anticonvulsant, antidiabetic, antioxidant, adenosine receptor antagonist, and significant cytotoxic activities. Hence, this privileged scaffold could act as an important candidate in the field of drug development. Many synthetic protocols have been developed to efficiently synthesize this fused heterocycle and its derivatives. Triazole and quinazoline rings fused at different positions which occurs in various isomeric forms such as, 1,2,4-triazolo[1,5-c]quinazoline, 1,2,4-triazolo[1,5-a]quinazoline, 1,2,4-triazolo[4,3-c]quinazoline, 1,2,4-triazolo[4,3-a]quinazoline, etc. This book chapter covers the synthesis of various isomeric forms of triazoloquinazoline as well as their biological activities.

Part of the book: Recent Advances on Quinazoline